Announcement on Change of Drug Production License
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Shaanxi Kanghui Pharmaceutical Co., Ltd. has announced a change in its drug production license.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shaanxi Kanghui Pharmaceutical Co., Ltd. on 6ix
Earlier from Shaanxi Kanghui Pharmaceutical
- Notice on Convening the 3rd Extraordinary General Meeting in 2025
- Announcement on Progress in Lawsuit and Receipt of Notice of Withdrawal of Lawsuit
- Announcement on Completing Change of Legal Representative and Renewing Business License
- Announcement on Implementing Change of the Company's Stock Name
- Announcement on Convening the 2025 Semi-annual Performance Briefing
Later from Shaanxi Kanghui Pharmaceutical
- Announcement on Wholly-owned Subsidiary Completing Industrial and Commercial Change Registration
- Announcement on Applying for Arbitration Regarding Performance Compensation Matters
- Announcement on Resolutions of the 3rd General Meeting in 2025
- Announcement on Increasing the Estimated Amount for Daily Related Party Transactions in 2025
- Announcement on Applying for Arbitration Regarding Performance Compensation Matters and Accumulated Litigation
Follow Shaanxi Kanghui Pharmaceutical into a list and get an email when it puts out news.
Follow Shaanxi Kanghui Pharmaceutical